<DOC>
	<DOCNO>NCT00324714</DOCNO>
	<brief_summary>RATIONALE : Bisphosphonates , risedronate , may help improve bone health prevent osteoporosis postmenopausal woman . It yet know whether risedronate effective improve bone mineral density bone health woman ductal carcinoma situ . PURPOSE : This randomized phase III trial study risedronate see well work compare placebo improve bone mineral density bone health postmenopausal woman ductal carcinoma situ enrol clinical trial CRUK-IBIS-II-DCIS ( CRUK : Cancer Research UK ) ( DCIS : Ductal carcinoma situ ) .</brief_summary>
	<brief_title>Risedronate Improving Bone Mineral Density Bone Health Postmenopausal Women With Ductal Carcinoma In Situ Enrolled Clinical Trial CRUK-IBIS-II-DCIS</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare change bone spine femur postmenopausal woman ductal carcinoma situ treat anastrozole v placebo protocol CRUK-IBIS-II-DCIS . - Determine effect bisphosphonate treatment bone mineral density bone metabolism patient receive anastrozole protocol CRUK-IBIS-II-DCIS osteoporotic moderately severely osteopenic baseline . Secondary - Correlate change level biochemical marker bone metabolism longer-term change bone mineral density , measure dual-energy x-ray absorptiometry ( DXA ) . OUTLINE : This multicenter , partially randomize , double-blind study . Patients stratify accord bone mineral density ( T-score ) measurement ( ≥ -1.5 v -2.5 &lt; -1.5 v -4.0 &lt; -2.5 ≤ 2 low-trauma vertebral fracture ) . Patients stratum I stratify accord calcium cholecalciferol ( vitamin D ) supplementation ( yes v ) use risedronate study ( yes v ) . Patients stratum II stratify accord randomize treatment protocol CRUK-IBIS-II-DCIS ( yes v ) . - Stratum I ( T-score ≥ -1.5 ) : Patients undergo dual-energy x-ray absorptiometry ( DXA ) scan baseline 1 , 3 , 5 , 7 year . Patients develop osteoporosis ( T-score &lt; -2.5 ) remove study receive open-label bisphosphonates . - Stratum II ( T-score -2.5 &lt; -1.5 [ moderate severe osteopenia ] ) : Patients undergo DXA scan stratum I . Patients also randomize ( double-blind ) 1 2 treatment arm . - Arm I : Patients receive oral risedronate week 5 year . - Arm II : Patients receive oral placebo week 5 year . Patients either arm develop osteoporosis AND drop T-score 1 unit remove study receive open-label bisphosphonates . - Stratum III ( T-score -4.0 &lt; -2.5 OR ≤ 2 low trauma vertebral fracture [ osteoporosis ] ) : Patients undergo DXA scan stratum I . Patients also receive oral risedronate ( current bisphosphonate ) week 5 year . Blood sample correlative study ( e.g. , bone biomarkers , serum estradiol ) collect baseline 6 12 month . After completion study treatment , patient follow periodically . PROJECTED ACCRUAL : A total 1,000 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Carcinoma Situ</mesh_term>
	<mesh_term>Risedronate Sodium</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis ductal carcinoma situ within past 6 month Locally excise tumorfree margin least 1 mm Currently enrol protocol CRUKIBISIIDCIS AND randomize receive either anastrozole placebo No Tscore &lt; 4.0 and/or &gt; 2 low trauma vertebral fracture dualenergy xray absorptiometry ( DXA ) Hormone receptor status : Estrogen progesterone receptor positive tumor PATIENT CHARACTERISTICS : Female patient Postmenopausal No prior bilateral hip fracture bilateral hip prostheses No concurrent metabolic bone disease , include follow : Paget 's disease Osteogenesis imperfecta Disorders calcium mineral metabolism Renal calculus Malabsorption Hypercalcemia hypocalcemia Hyperparathyroidism hypoparathyroidism Hyperthyroidism hypothyroidism Patients stable replacement therapy allow provide euthyroid PRIOR CONCURRENT THERAPY : More 12 month since prior medication affect bone metabolism , include follow : Estrogen Any bisphosphonate Parathyroid hormone Calcitonin Oral systemic glucocorticoid</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>osteoporosis</keyword>
	<keyword>ductal breast carcinoma situ</keyword>
	<keyword>breast cancer situ</keyword>
</DOC>